Hydralazine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "==Sources==" to "==References==") |
Neil.m.young (talk | contribs) (Text replacement - "* " to "*") |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
* HTN: 10 - 50 mg PO QID | *HTN: 10 - 50 mg PO QID | ||
* Hypertensive crisis: 10-20 mg IM/IV q2-4h | *Hypertensive crisis: 10-20 mg IM/IV q2-4h | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 25: | Line 25: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
* mitral valvular rheumatic heart disease | *mitral valvular rheumatic heart disease | ||
* Caution if renal impairment | *Caution if renal impairment | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
Revision as of 14:41, 4 July 2016
General
- Type: Vasodilator
- Dosage Forms: 10, 25, 50, 100; PO, IM, IV
- Common Trade Names: Apresoline
Adult Dosing
- HTN: 10 - 50 mg PO QID
- Hypertensive crisis: 10-20 mg IM/IV q2-4h
Pediatric Dosing
- Hypertensive Crisis:
- 1 mo - 12 years: 0.1 - 0.5 mg/kg IM/IV q4-6h, max dose of 20 mg
- > 12 years old: 10 - 20 mg IV q2-4h
Special Populations
- Pregnancy Rating: C
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl 10-50: give q8h, CrCl <10, give q8-16h
- Pediatric: CrCl 10-50: give q8h, CrCl <10, give q8-16h
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- mitral valvular rheumatic heart disease
- Caution if renal impairment
Adverse Reactions
Serious
- MI
- neutropenia
- lupus erythematosus
- peripheral neuritis
Common
- headache
- tachycardia
- angina
- nausea/vomiting
- rash
Pharmacology
- Half-life: 3-7 hours
- Metabolism: liver
- Excretion: urine, feces
- Mechanism of Action: directly dilates peripheral vessels